COVID-19 Oral Antiviral Agents

In this episode, Renslow Sherer, MD, discusses key data on COVID-19 oral antiviral agents—molnupiravir and nirmatrelvir (PF-07321332) plus ritonavir—for nonhospitalized adults with mild to moderate COVID-19, including:

• EPIC-HR study of nirmatrelvir (PF-07321332) plus ritonavir
  • Safety data
  • Efficacy data
• MOVe-OUT study of molnupiravir
  • Safety data
  • Efficacy data
• Roles in treatment of COVID-19
  • Timing of treatment

Presenter:

Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois

Review the downloadable slideset at:
https://bit.ly/31wi1Qi

Link to full program:
https://bit.ly/3EH2485

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.